Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 209 entries
Sorted by: Best Match Show Resources per page
Photocurable Bioinks for the 3D Pharming of Combination Therapies.

Polymers

Acosta-Vélez GF, Linsley CS, Zhu TZ, Wu W, Wu BM.
PMID: 30961297
Polymers (Basel). 2018 Dec 11;10(12). doi: 10.3390/polym10121372.

Combination therapies mediate drug synergy to improve treatment efficacy and convenience, leading to higher levels of compliance. However, there are challenges with their manufacturing as well as reduced flexibility in dosing options. This study reports on the design and...

Cite
Acosta-Vélez GF, Linsley CS, Zhu TZ, et al. Photocurable Bioinks for the 3D Pharming of Combination Therapies. Polymers (Basel). 2018;10(12)doi: 10.3390/polym10121372.
Acosta-Vélez, G. F., Linsley, C. S., Zhu, T. Z., Wu, W., & Wu, B. M. (2018). Photocurable Bioinks for the 3D Pharming of Combination Therapies. Polymers, 10(12), . https://doi.org/10.3390/polym10121372
Acosta-Vélez, Giovanny F, et al. "Photocurable Bioinks for the 3D Pharming of Combination Therapies." Polymers vol. 10,12 (2018). doi: https://doi.org/10.3390/polym10121372
Acosta-Vélez GF, Linsley CS, Zhu TZ, Wu W, Wu BM. Photocurable Bioinks for the 3D Pharming of Combination Therapies. Polymers (Basel). 2018 Dec 11;10(12). doi: 10.3390/polym10121372. PMID: 30961297; PMCID: PMC6401852.
Copy Download .nbib Format: NLM
Pulmonary vein thrombosis secondary to tuberculosis in a non-HIV infected patient.

Respiratory medicine case reports

Raru Y, Abouzid M, Zeid F, Teka S.
PMID: 30560051
Respir Med Case Rep. 2018 Dec 05;26:91-93. doi: 10.1016/j.rmcr.2018.11.020. eCollection 2019.

Our patient is a 67-year-old male with a past medical history significant for hypertension and hyperlipidemia came to a hospital with hemoptysis. He was also having cough and shortness of breath for the last 1 month. He said that...

Cite
Raru Y, Abouzid M, Zeid F, et al. Pulmonary vein thrombosis secondary to tuberculosis in a non-HIV infected patient. Respir Med Case Rep. 2018;26:91-93doi: 10.1016/j.rmcr.2018.11.020.
Raru, Y., Abouzid, M., Zeid, F., & Teka, S. (2019). Pulmonary vein thrombosis secondary to tuberculosis in a non-HIV infected patient. Respiratory medicine case reports, 2691-93. https://doi.org/10.1016/j.rmcr.2018.11.020
Raru, Yonas, et al. "Pulmonary vein thrombosis secondary to tuberculosis in a non-HIV infected patient." Respiratory medicine case reports vol. 26 (2019): 91-93. doi: https://doi.org/10.1016/j.rmcr.2018.11.020
Raru Y, Abouzid M, Zeid F, Teka S. Pulmonary vein thrombosis secondary to tuberculosis in a non-HIV infected patient. Respir Med Case Rep. 2018 Dec 05;26:91-93. doi: 10.1016/j.rmcr.2018.11.020. eCollection 2019. PMID: 30560051; PMCID: PMC6288975.
Copy Download .nbib Format: NLM
Type IV RTA in Chronic Adrenal Insufficiency and Concomitant Lisinopril Treatment.

Case reports in endocrinology

Galbiati F.
PMID: 33133704
Case Rep Endocrinol. 2020 Oct 19;2020:8897112. doi: 10.1155/2020/8897112. eCollection 2020.

Type IV renal tubular acidosis (RTA) is the only RTA characterized by hyperkalemia, and it is caused by a true aldosterone deficiency or renal tubular aldosterone hyporesponsiveness. It is frequent among hospitalized patients as it is related to type...

Cite
Galbiati F. Type IV RTA in Chronic Adrenal Insufficiency and Concomitant Lisinopril Treatment. Case Rep Endocrinol. 2020;2020:8897112doi: 10.1155/2020/8897112.
Galbiati, F. (2020). Type IV RTA in Chronic Adrenal Insufficiency and Concomitant Lisinopril Treatment. Case reports in endocrinology, 20208897112. https://doi.org/10.1155/2020/8897112
Galbiati, Francesca. "Type IV RTA in Chronic Adrenal Insufficiency and Concomitant Lisinopril Treatment." Case reports in endocrinology vol. 2020 (2020): 8897112. doi: https://doi.org/10.1155/2020/8897112
Galbiati F. Type IV RTA in Chronic Adrenal Insufficiency and Concomitant Lisinopril Treatment. Case Rep Endocrinol. 2020 Oct 19;2020:8897112. doi: 10.1155/2020/8897112. eCollection 2020. PMID: 33133704; PMCID: PMC7591977.
Copy Download .nbib Format: NLM
Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario.

Journal of the advanced practitioner in oncology

Allman KD, Ryan JC, Clair A, Yenser-Wood S.
PMID: 33457061
J Adv Pract Oncol. 2019 Jul;10(5):483-493. doi: 10.6004/jadpro.2019.10.5.6. Epub 2019 Jul 01.

This patient case is fictional and does not represent events or a response from an actual patient. The authors developed this fictional case for educational purposes only. Brady, a 54-year-old white male, was diagnosed with metastatic renal cell carcinoma...

Cite
Allman KD, Ryan JC, Clair A, et al. Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. J Adv Pract Oncol. 2019;10(5):483-493doi: 10.6004/jadpro.2019.10.5.6.
Allman, K. D., Ryan, J. C., Clair, A., & Yenser-Wood, S. (2019). Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. Journal of the advanced practitioner in oncology, 10(5), 483-493. https://doi.org/10.6004/jadpro.2019.10.5.6
Allman, Kimberly D, et al. "Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario." Journal of the advanced practitioner in oncology vol. 10,5 (2019): 483-493. doi: https://doi.org/10.6004/jadpro.2019.10.5.6
Allman KD, Ryan JC, Clair A, Yenser-Wood S. Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. J Adv Pract Oncol. 2019 Jul;10(5):483-493. doi: 10.6004/jadpro.2019.10.5.6. Epub 2019 Jul 01. PMID: 33457061; PMCID: PMC7779571.
Copy Download .nbib Format: NLM
Structural changes in pH-responsive gelatin/hydroxypropyl methylcellulose phthalate blends aimed at drug-release systems.

International journal of biological macromolecules

Nogami S, Kadota K, Uchiyama H, Arima-Osonoi H, Iwase H, Tominaga T, Yamada T, Takata SI, Shibayama M, Tozuka Y.
PMID: 34537299
Int J Biol Macromol. 2021 Nov 01;190:989-998. doi: 10.1016/j.ijbiomac.2021.09.074. Epub 2021 Sep 17.

The present study aimed to investigate the thermal- and pH-dependent gelation behavior of gelatin/HPMCP blends using ultraviolet (UV) spectrophotometry, viscoelasticity, and dynamic light scattering (DLS). We found that the release of lisinopril from gelatin/HPMCP gels can be inhibited at...

Cite
Nogami S, Kadota K, Uchiyama H, et al. Structural changes in pH-responsive gelatin/hydroxypropyl methylcellulose phthalate blends aimed at drug-release systems. Int J Biol Macromol. 2021;190:989-998doi: 10.1016/j.ijbiomac.2021.09.074.
Nogami, S., Kadota, K., Uchiyama, H., Arima-Osonoi, H., Iwase, H., Tominaga, T., Yamada, T., Takata, S. I., Shibayama, M., & Tozuka, Y. (2021). Structural changes in pH-responsive gelatin/hydroxypropyl methylcellulose phthalate blends aimed at drug-release systems. International journal of biological macromolecules, 190989-998. https://doi.org/10.1016/j.ijbiomac.2021.09.074
Nogami, Satoshi, et al. "Structural changes in pH-responsive gelatin/hydroxypropyl methylcellulose phthalate blends aimed at drug-release systems." International journal of biological macromolecules vol. 190 (2021): 989-998. doi: https://doi.org/10.1016/j.ijbiomac.2021.09.074
Nogami S, Kadota K, Uchiyama H, Arima-Osonoi H, Iwase H, Tominaga T, Yamada T, Takata SI, Shibayama M, Tozuka Y. Structural changes in pH-responsive gelatin/hydroxypropyl methylcellulose phthalate blends aimed at drug-release systems. Int J Biol Macromol. 2021 Nov 01;190:989-998. doi: 10.1016/j.ijbiomac.2021.09.074. Epub 2021 Sep 17. PMID: 34537299.
Copy Download .nbib Format: NLM
Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities.

Frontiers in pharmacology

Medhora M, Phadnis P, Narayanan J, Gasperetti T, Zielonka J, Moulder JE, Fish BL, Szabo A.
PMID: 33986677
Front Pharmacol. 2021 Apr 27;12:646076. doi: 10.3389/fphar.2021.646076. eCollection 2021.

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic,...

Cite
Medhora M, Phadnis P, Narayanan J, et al. Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities. Front Pharmacol. 2021;12:646076doi: 10.3389/fphar.2021.646076.
Medhora, M., Phadnis, P., Narayanan, J., Gasperetti, T., Zielonka, J., Moulder, J. E., Fish, B. L., & Szabo, A. (2021). Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities. Frontiers in pharmacology, 12646076. https://doi.org/10.3389/fphar.2021.646076
Medhora, Meetha, et al. "Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities." Frontiers in pharmacology vol. 12 (2021): 646076. doi: https://doi.org/10.3389/fphar.2021.646076
Medhora M, Phadnis P, Narayanan J, Gasperetti T, Zielonka J, Moulder JE, Fish BL, Szabo A. Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities. Front Pharmacol. 2021 Apr 27;12:646076. doi: 10.3389/fphar.2021.646076. eCollection 2021. PMID: 33986677; PMCID: PMC8111401.
Copy Download .nbib Format: NLM
Molecular Changes in miRNA in Irradiated Rat Kidneys: Role of miR-34a and its Vascular Targets in the Notch Pathway.

Radiation research

Gao F, Dong W, Liu P, Narayanan J, Fish BL, Jacobs ER, Medhora M.
PMID: 34330145
Radiat Res. 2021 Dec 01;196(6):611-622. doi: 10.1667/RADE-20-00078.1.

The mechanism(s) of vascular regression in adult organs remains an unexplored gap. Irradiation to the kidney results in vascular regression and renal failure. The goal of this work was to determine molecular mechanism(s) of radiation-induced vascular regression and its...

Cite
Gao F, Dong W, Liu P, et al. Molecular Changes in miRNA in Irradiated Rat Kidneys: Role of miR-34a and its Vascular Targets in the Notch Pathway. Radiat Res. 2021;196(6):611-622doi: 10.1667/RADE-20-00078.1.
Gao, F., Dong, W., Liu, P., Narayanan, J., Fish, B. L., Jacobs, E. R., & Medhora, M. (2021). Molecular Changes in miRNA in Irradiated Rat Kidneys: Role of miR-34a and its Vascular Targets in the Notch Pathway. Radiation research, 196(6), 611-622. https://doi.org/10.1667/RADE-20-00078.1
Gao, Feng, et al. "Molecular Changes in miRNA in Irradiated Rat Kidneys: Role of miR-34a and its Vascular Targets in the Notch Pathway." Radiation research vol. 196,6 (2021): 611-622. doi: https://doi.org/10.1667/RADE-20-00078.1
Gao F, Dong W, Liu P, Narayanan J, Fish BL, Jacobs ER, Medhora M. Molecular Changes in miRNA in Irradiated Rat Kidneys: Role of miR-34a and its Vascular Targets in the Notch Pathway. Radiat Res. 2021 Dec 01;196(6):611-622. doi: 10.1667/RADE-20-00078.1. PMID: 34330145.
Copy Download .nbib Format: NLM
The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy.

Journal of neuromuscular diseases

Lowe J, Wodarcyk AJ, Floyd KT, Rastogi N, Schultz EJ, Swager SA, Chadwick JA, Tran T, Raman SV, Janssen PM, Rafael-Fortney JA.
PMID: 27110493
J Neuromuscul Dis. 2015;2(3):257-268. doi: 10.3233/JND-150099. Epub 2015 Sep 02.

BACKGROUND: Angiotensin converting enzyme inhibitors (ACEi) are the current standard of care treatment for cardiac dysfunction in Duchenne muscular dystrophy patients. We previously showed treatment with an ACEi plus mineralocorticoid receptor (MR) antagonist improves limb and respiratory skeletal muscles,...

Cite
Lowe J, Wodarcyk AJ, Floyd KT, et al. The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2015;2(3):257-268doi: 10.3233/JND-150099.
Lowe, J., Wodarcyk, A. J., Floyd, K. T., Rastogi, N., Schultz, E. J., Swager, S. A., Chadwick, J. A., Tran, T., Raman, S. V., Janssen, P. M., & Rafael-Fortney, J. A. (2015). The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy. Journal of neuromuscular diseases, 2(3), 257-268. https://doi.org/10.3233/JND-150099
Lowe, Jeovanna, et al. "The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy." Journal of neuromuscular diseases vol. 2,3 (2015): 257-268. doi: https://doi.org/10.3233/JND-150099
Lowe J, Wodarcyk AJ, Floyd KT, Rastogi N, Schultz EJ, Swager SA, Chadwick JA, Tran T, Raman SV, Janssen PM, Rafael-Fortney JA. The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2015;2(3):257-268. doi: 10.3233/JND-150099. Epub 2015 Sep 02. PMID: 27110493; PMCID: PMC4838202.
Copy Download .nbib Format: NLM
A Double-Blind Crossover Comparison of Nebivolol and Lisinopril in the Treatment of Ambulatory Hypertension.

American journal of therapeutics

Lacourcière Y, Lefebvre J, Poirier L, Archambault F, Arnott W.
PMID: 11835070
Am J Ther. 1994 Jun;1(1):74-80. doi: 10.1097/00045391-199406000-00012.

Twenty-four-hour ambulatory blood pressure (ABP) monitoring was used as a measure of drug efficacy and criterion for inclusion of 29 patients with primary hypertension in a double-blind crossover comparison of the novel cardioselective beta-blocker nebivolol (2.5--10 mg) with lisinopril...

Cite
Lacourcière Y, Lefebvre J, Poirier L, et al. A Double-Blind Crossover Comparison of Nebivolol and Lisinopril in the Treatment of Ambulatory Hypertension. Am J Ther. 1994;1(1):74-80doi: 10.1097/00045391-199406000-00012.
Lacourcière, Y., Lefebvre, J., Poirier, L., Archambault, F., & Arnott, W. (1994). A Double-Blind Crossover Comparison of Nebivolol and Lisinopril in the Treatment of Ambulatory Hypertension. American journal of therapeutics, 1(1), 74-80. https://doi.org/10.1097/00045391-199406000-00012
Lacourcière, Yves, et al. "A Double-Blind Crossover Comparison of Nebivolol and Lisinopril in the Treatment of Ambulatory Hypertension." American journal of therapeutics vol. 1,1 (1994): 74-80. doi: https://doi.org/10.1097/00045391-199406000-00012
Lacourcière Y, Lefebvre J, Poirier L, Archambault F, Arnott W. A Double-Blind Crossover Comparison of Nebivolol and Lisinopril in the Treatment of Ambulatory Hypertension. Am J Ther. 1994 Jun;1(1):74-80. doi: 10.1097/00045391-199406000-00012. PMID: 11835070.
Copy Download .nbib Format: NLM
ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat.

Journal of cardiovascular pharmacology and therapeutics

Hollenberg NK, Guidi E.
PMID: 10684494
J Cardiovasc Pharmacol Ther. 1998 Apr;3(2):161-170. doi: 10.1177/107424849800300209.

BACKGROUND: Substantial evidence has accumulated for the intrarenal generation of functionally important quantities of angiotensin II (Ang II). To assess the possibility that Ang II generation occurs beyond a barrier to diffusion from the vascular compartment, six angiotensin-converting enzyme...

Cite
Hollenberg NK, Guidi E. ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. J Cardiovasc Pharmacol Ther. 1998;3(2):161-170doi: 10.1177/107424849800300209.
Hollenberg, N. K., & Guidi, E. (1998). ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. Journal of cardiovascular pharmacology and therapeutics, 3(2), 161-170. https://doi.org/10.1177/107424849800300209
Hollenberg, and Guidi. "ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat." Journal of cardiovascular pharmacology and therapeutics vol. 3,2 (1998): 161-170. doi: https://doi.org/10.1177/107424849800300209
Hollenberg NK, Guidi E. ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat. J Cardiovasc Pharmacol Ther. 1998 Apr;3(2):161-170. doi: 10.1177/107424849800300209. PMID: 10684494.
Copy Download .nbib Format: NLM
ACE inhibitors versus diuretics: ALLHAT versus ANBP2.

Expert opinion on pharmacotherapy

Doggrell SA.
PMID: 12740004
Expert Opin Pharmacother. 2003 May;4(5):825-8. doi: 10.1517/14656566.4.5.825.

The ALLHAT (The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial) trial enrolled hypertensive patients with at least one additional risk factor for coronary heart disease (CHD) to a comparison of the diuretic chlorthalidone, the calcium channel blocker,...

Cite
Doggrell SA. ACE inhibitors versus diuretics: ALLHAT versus ANBP2. Expert Opin Pharmacother. 2003;4(5):825-8doi: 10.1517/14656566.4.5.825.
Doggrell, S. A. (2003). ACE inhibitors versus diuretics: ALLHAT versus ANBP2. Expert opinion on pharmacotherapy, 4(5), 825-8. https://doi.org/10.1517/14656566.4.5.825
Doggrell, Sheila A. "ACE inhibitors versus diuretics: ALLHAT versus ANBP2." Expert opinion on pharmacotherapy vol. 4,5 (2003): 825-8. doi: https://doi.org/10.1517/14656566.4.5.825
Doggrell SA. ACE inhibitors versus diuretics: ALLHAT versus ANBP2. Expert Opin Pharmacother. 2003 May;4(5):825-8. doi: 10.1517/14656566.4.5.825. PMID: 12740004.
Copy Download .nbib Format: NLM
Relation of renin-angiotensin system gene polymorphisms and expressions with the efficacy of antihypertensive drugs.

Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA

Wei XL, Zhao GS, Wang GL, Li DY, Guo JZ.
PMID: 12426159
Di Yi Jun Yi Da Xue Xue Bao. 2001;21(12):898-901.

OBJECTIVE: To investigate the relation of renin-angiotensin system (RA3) gene polymorphisms and expressions with the clinical efficacy of antihypertensive drugs. METHODS: This randomized, single-blind study consisted of 90 patients with essential hypertension, who were divided into losartan, lisinopril and...

Cite
Wei XL, Zhao GS, Wang GL, et al. Relation of renin-angiotensin system gene polymorphisms and expressions with the efficacy of antihypertensive drugs. Di Yi Jun Yi Da Xue Xue Bao. 2001;21(12):898-901
Wei, X. L., Zhao, G. S., Wang, G. L., Li, D. Y., & Guo, J. Z. (2001). Relation of renin-angiotensin system gene polymorphisms and expressions with the efficacy of antihypertensive drugs. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 21(12), 898-901.
Wei, Xiang-Long, et al. "Relation of renin-angiotensin system gene polymorphisms and expressions with the efficacy of antihypertensive drugs." Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA vol. 21,12 (2001): 898-901.
Wei XL, Zhao GS, Wang GL, Li DY, Guo JZ. Relation of renin-angiotensin system gene polymorphisms and expressions with the efficacy of antihypertensive drugs. Di Yi Jun Yi Da Xue Xue Bao. 2001;21(12):898-901. PMID: 12426159.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 209 entries